{"id":"NCT01281475","sponsor":"Wen-Hann Tan","briefTitle":"A Trial of Levodopa in Angelman Syndrome","officialTitle":"A Phase 2 Randomized Placebo-Controlled Trial of Levodopa in Angelman Syndrome","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2011-01","primaryCompletion":"2015-07","completion":"2015-07","firstPosted":"2011-01-24","resultsPosted":"2017-01-13","lastUpdate":"2020-07-15"},"enrollment":67,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Angelman Syndrome"],"interventions":[{"type":"DRUG","name":"Levodopa","otherNames":["Sinemet","L-dopa"]},{"type":"DRUG","name":"Placebo Oral Capsule","otherNames":[]}],"arms":[{"label":"Levodopa","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is designed to determine whether levodopa will lead to an improvement in the development and tremor in children with Angelman syndrome (AS).\n\nIt has been suggested that levodopa, a medication that is usually used to treat Parkinson disease in adults, may help children with AS in their overall development and reduce the tremor that some of them have.\n\nIf levodopa is found to be beneficial for children with AS, this could lead to a new treatment for AS.\n\nFunding Source - FDA-OOPD","primaryOutcome":{"measure":"Bayley Cognitive Age Equivalent at 1 Year","timeFrame":"12 months","effectByArm":[{"arm":"Levodopa","deltaMin":19,"sd":7},{"arm":"Placebo","deltaMin":19,"sd":8}],"pValues":[{"comp":"OG000 vs OG001","p":"0.75"}]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":7,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":33},"commonTop":["Seizures"]}}